ATP2C1 blockers(ATPase secretory pathway Ca2+ transporting 1 blockers), GABRA1 agonists(gamma-aminobutyric acid type A receptor subunit alpha1 agonists), GLRA1 agonists(glycine receptor alpha 1 agonists)

Therapeutic Areas

Other Diseases

Active Indication

Anesthesia

Inactive Indication-

Originator Organization

Baxter Healthcare Corp.

Active Organization

Baxter Healthcare Corp.

Hebei Yipin Pharmaceutical Co., Ltd.

Inactive Organization

Yichang Humanwell Pharmaceuticals Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

US (18 Dec 1979),

Anesthesia

RegulationFast Track (US)

Structure

Molecular FormulaC3H2ClF5O

InChIKeyPIWKPBJCKXDKJR-UHFFFAOYSA-N

CAS Registry26675-46-7

145

Clinical Trials associated with Isoflurane

NCT06252207 / Not yet recruitingNot ApplicableIIT

Desflurane Versus Isoflurane for Speeding Postanesthetic Recovery and Hospital Discharge: a Cluster Randomized Crossover Trial

The investigators thus propose a comparative effectiveness quality improvement project to evaluate the feasibility of switching from near-exclusive use of isoflurane in adult general surgical patients to Desflurane.

Start Date15 Jan 2025

Sponsor / Collaborator

The Cleveland Clinic Foundation

NCT06624592 / Not yet recruitingPhase 3IIT

Sevoflurane/Dexmedetomidine vs. Isoflurane and Their Effects on Pediatric Emergence Delirium

The purpose of this study is to measure the incidences of pediatric emergence delirium between the group receiving Isoflurane and the group receiving Sevoflurane plus intravenous push dexmedetomidine.

Start Date01 Nov 2024

Sponsor / Collaborator

Mayo Clinic

NCT06625606 / RecruitingNot ApplicableIIT

Continuous Spinal Anesthesia for Patients Planned For Major Orthopedic Surgeries: Versus Single-Shot Spinal Anesthesia: A Case-Control Comparative Study

A study was conducted to compare the effectiveness of continuous spinal anesthesia (CSA), single-shot spinal anesthesia (SSSA), and general anesthesia (GA) in patients over 60 years of age undergoing elective surgical repair of a fractured neck of femur. One hundred and five patients were randomly assigned to one of the three groups. The SSSA group received a single intrathecal injection of isobaric bupivacaine 0.5%, while the CSA group received multiple injections of the same anesthetic through a catheter placed in the subarachnoid space. The GA group received isoflurane anesthesia. Intraoperatively, blood pressure was monitored to assess the frequency of hypotension and the required dose of ephedrine. Additionally, the total dose of bupivacaine administered and the frequency of intraoperative fentanyl were recorded. Postoperatively, the duration of postoperative analgesia, pain scores, and need for additional pain medication were evaluated.

Start Date01 Sep 2024

Sponsor / Collaborator

Benha University

100 Clinical Results associated with Isoflurane

100 Translational Medicine associated with Isoflurane

100 Patents (Medical) associated with Isoflurane

12,894

Literatures (Medical) associated with Isoflurane

01 Mar 2025·Medical Gas Research

Anesthesia and its environmental impact: approaches to minimize exposure to anesthetic gases and reduce waste

Review

Author: Siddiqui, Khalid Maudood ; Yousuf, Muhammad Saad ; Ahmed, Syed Shabbir ; Ullah, Hameed ; Latif, Asad ; Samad, Khalid

In today’s era of modern healthcare, the intersection between medical practices and environmental responsibility has gained significant attention. One such area of focus is the practice of anesthesia, which plays a crucial role in various surgical procedures. Anesthetics such as nitrous oxide and volatile halogenated ethers (desflurane, isoflurane, sevoflurane) are examples of medical gases that are strong greenhouse gases that contribute to global warming. During medical procedures, most of these anesthetic agents are released into the atmosphere, which exacerbates their influence on the environment. Also anesthesia delivery systems have traditionally utilized high flow rates of gases, leading to not only excessive consumption but also a considerable environmental impact in terms of greenhouse gas emissions. However, the emergence of low-flow anesthesia (LFA) presents a promising solution for achieving emission reduction and cost savings, thereby aligning healthcare practices with sustainability goals. Understanding LFA involves the administration of anesthetic gases to patients at reduced flow rates compared to conventional high-flow methods. This practice requires precision in gas delivery, often incorporating advanced monitoring and control systems. By optimizing gas flow to match the patient’s requirements, LFA minimizes wastage and excessive gas release into the environment, subsequently curbing the carbon footprint associated with healthcare operations. Decreasing volatile anesthetic delivery provides safe and effective strategies for anesthesia providers to decrease costs and reduce environmental pollution. Current literature support in favor of LFA represents an area of cost containment and an opportunity to lessen the environmental impact of anesthesia. This article will cover the concept of LFA, the distinctions between low flow and minimal flow, and the potential advantages of LFA, such as those related to patient safety, the environment, and the economy.

01 Jan 2025·Equine veterinary journal

Low‐dose sugammadex reverses moderate rocuronium‐induced neuromuscular block in horses

Article

Author: Sakai, Daniel M. ; Martin‐Flores, Manuel ; Araos, Joaquin ; Campoy, Luis

Abstract:

Background:

Neuromuscular block (NMB) during general anaesthesia has an implicit risk of inadvertent residual NMB during recovery. Reversal of NMB is commonly encouraged to decrease this risk, and has historically been performed with neostigmine/atropine, two agents with important cardiac and gastrointestinal side effects. Sugammadex is a new selective relaxant binding agent that can reverse rocuronium‐induced NMB efficiently and without these complications. Recommended doses are possibly cost‐prohibitive.

Objectives:

To measure the recovery time from rocuronium‐NMB after administration of low‐dose sugammadex, compared with spontaneous recovery.

Study design:

Nonrandomised in vivo experiments.

Methods:

Fourteen adult horses undergoing different research procedures were anaesthetised with detomidine and isoflurane. All horses received NMB with rocuronium 0.3 mg/kg IV. Neuromuscular function was measured with acceleromyographic train‐of‐four (TOF) ratio. Recovery occurred spontaneously in five horses weighing (median [range]) 548 (413–594) kg and was enhanced with sugammadex 200 mg (total dose) in nine horses (433 [362–515]) kg. Recovery time from moderate NMB to a TOF ratio 1.0, and total duration of NMB were compared between groups. Cases of recurarisation (decrease in the TOF ratio <0.9 after recovery) were identified within 30 min after sugammadex.

Results:

The dose of sugammadex was 0.46 (0.39–0.55) mg/kg. The recovery period lasted 21 (17–39) minutes for spontaneous and 4 (3–7) minutes for sugammadex. Total duration of NMB was 58 (41–70) minutes for spontaneous and 36 (21–43) for sugammadex (both p ≤ 0.003). There were no instances of recurarisation.

Main limitations:

Small sample size.

Conclusions:

A dose of sugammadex of approximately 0.5 mg/kg substantially shortened the recovery period from rocuronium‐induced NMB from a median of 21 to 4 min, when given at a moderate depth of NMB. No recurarisation was observed within the next 30 min.

01 Jan 2025·BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS

Anaesthetics disrupt complex I-linked respiration and reverse the ATP synthase

Article

Author: Lane, Nick ; Rodriguez, Enrique ; Peng, Bella

The mechanism of volatile general anaesthetics has long been a mystery. Anaesthetics have no structural motifs in common, beyond lipid solubility, yet all exert a similar effect. The fact that the inert gas xenon is an anaesthetic suggests their common mechanism might relate to physical rather than chemical properties. Electron transfer through chiral proteins can induce spin polarization. Recent work suggests that anaesthetics dissipate spin polarization during electron transfer to oxygen, slowing respiration. Here we show that the volatile anaesthetics isoflurane and sevoflurane specifically disrupt complex I-linked respiration in the thoraces of Drosophila melanogaster, with less effect on maximal respiration. Suppression of complex I-linked respiration was greatest with isoflurane. Using high-resolution tissue fluorespirometry, we show that these anaesthetics simultaneously increase mitochondrial membrane potential, implying reversal of the ATP synthase. Inhibition of ATP synthase with oligomycin prevented respiration and increased membrane potential back to the maximal (LEAK state) potential. Magnesium-green fluorescence predicted a collapse in ATP availability following a single anaesthetic dose, consistent with ATP hydrolysis through reversal of the ATP synthase. Raised membrane potential corresponded to a rise in ROS flux, especially with isoflurane. Anaesthetic doses causing respiratory suppression were in the same range as those that induce anaesthesia, although we could not establish tissue concentrations. Our findings show that anaesthetics suppress complex I-linked respiration with concerted downstream effects. But we cannot explain why only mutations in complex I, and not elsewhere in the electron-transfer system, confer hypersensitivity to anaesthetics.

News (Medical) associated with Isoflurane

29 May 2024

·www.prnewswire.com

Sedana Medical completes patient recruitment for its clinical program in the US

STOCKHOLM, May 29, 2024 /PRNewswire/ -- Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 2 phase III clinical trial in the United States. Earlier this spring, Sedana Medical reported the completion of enrolment to the parallel phase III clinical trial INSPiRE-ICU 1. The company anticipates topline results from both trials in the second half of 2024, with a planned New Drug Application (NDA) submission in the first quarter of 2025. "The completion of INSPiRE-ICU 2 concludes Sedana Medical´s clinical trials in the United States. Running this study together with esteemed clinical investigators from highly ranked academic centers such as Columbia, the Harvard-affiliated medical center Beth Israel Deaconess Medical Center and many others has been very exciting and rewarding. Many investigators from the participating sites have been excited to be part of our pioneering studies. The bedside experience in the studies has generated a lot of interest in using inhaled sedation in US practice, which we hope will be possible soon," said Peter Sackey, Chief Medical Officer of Sedana Medical. Peter Sackey further elaborated: "We now enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months are being collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results for the 30-day outcomes in both studies a few months´ apart before the end of this year, and a swift regulatory submission in Q1, 2025." "The inhaled sedative isoflurane, studied in this trial, is a mainstay of general anesthesia during surgery because of its unique and straightforward pharmacokinetic and pharmacodynamic profile, properties that may potentially also benefit ICU patients. We are very excited to complete enrolment in this trial and eagerly await results evaluating its potential use as a sedative for ventilator-dependent adult ICU patients in the US," said Jeremy Beitler, MD, MPH at Columbia University and Senior Lead Investigator for the INSPiRE-ICU 2 study. Johannes Doll, President and CEO of Sedana Medical, stated: "Completing enrolment of our clinical program marks an important milestone on our journey towards making inhaled sedation accessible to intensive care patients in the United States. I would like to sincerely thank all our clinical trial sites, partners, and the Sedana Medical team for this significant achievement. It makes me very proud that we have been able to convene this exceptional group of intensive care teams from some of the most prominent US hospitals. Their advice and support will be invaluable as we work towards launching our inhaled therapy on the US market." INSPiRE-ICU 1 and 2 are two identical randomized phase III trials, aiming to confirm the efficacy and safety for sedation with isoflurane delivered via Sedana Medical's unique medical device Sedaconda ACD. The primary endpoint is the proportion of time spent at adequate depth of sedation, compared with intravenous sedation using propofol. In addition, several important secondary endpoints are being studied, including opioid use, time to wake-up, cognitive recovery and spontaneous breathing. The first patient was included in April 2022, and 31 highly reputed clinics in the United States are involved in the two trials. The design of the US studies is similar to the Sedaconda study (SED001) successfully performed in Europe in 2017–2019, which resulted in market approval in 2021. For additional information, please contact: Johannes Doll, CEO, +46 (0)76 303 66 66 Johan Spetz, CFO, +46 (0)730 36 37 89 [email protected] About Sedana Medical Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient's life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care. Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors. Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm (SEDANA) and headquartered in Stockholm, Sweden. This information was brought to you by Cision The following files are available for download:

Phase 3

25 Apr 2024

·www.prnewswire.com

Sedana Medical completes patient recruitment for INSPiRE-ICU 1 clinical trial in the US

STOCKHOLM, April 25, 2024 /PRNewswire/ -- Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235 randomized patients remaining. The company anticipates topline results from both trials in the second half of 2024, with a planned New Drug Application (NDA) submission in the first quarter of 2025. "The completion of the INSPiRE-ICU 1 study marks a true milestone for Sedana Medical. Launching the randomized controlled multicenter studies across the large and diverse US healthcare landscape, in mixed surgical and medical ICUs with a different staffing and workflow compared to Europe, has been exciting. There is a lot of enthusiasm and interest in using inhaled sedation in US practice, which we hope will be possible soon", said Peter Sackey, Chief Medical Officer of Sedana Medical. Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025". "Working on these trials from initial design to implementation and completion has been very rewarding and has brought together many experienced clinical researchers in critical care across the US. We, and the clinicians at the bedside, are eager to see inhaled sedation available also in the US", said Christopher Hughes, Professor of Anesthesiology at Vanderbilt University Medical Center and Senior Lead Investigator for the INSPiRE-ICU 1 study. Johannes Doll, President and CEO of Sedana Medical, expressed gratitude, stating: "I would like to sincerely thank all our clinical trial sites, partners, and the Sedana Medical team for this significant achievement. It makes me very proud that we have been able to convene this exceptional group of intensive care teams from some of the most prominent US hospitals. Their advice and support will be invaluable as we work towards making the benefits of inhaled sedation accessible to patients in the United States." INSPiRE-ICU 1 and 2 are two identical randomized phase III trials, aiming to confirm the efficacy and safety for sedation with isoflurane delivered via Sedana Medical's unique medical device Sedaconda ACD. The primary endpoint is the proportion of time spent at adequate depth of sedation, compared with intravenous sedation using propofol. In addition, several important secondary endpoints are being studied, including opioid use, time to wake-up, cognitive recovery and spontaneous breathing. The first patient was included in April 2022, and 31 highly reputed clinics in the United States are involved in the two trials. The design of the US studies is similar to the Sedaconda study (SED001) successfully performed in Europe in 2017–2019, which resulted in market approval in 2021. For additional information, please contact: Johannes Doll, CEO, +46 (0)76 303 66 66 Johan Spetz, CFO, +46 (0)730 36 37 89 [email protected] About Sedana Medical Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient's life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care. Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors. Sedana Medical was founded in 2005, is listed on Nasdaq Stockholm (SEDANA) and headquartered in Stockholm, Sweden. This information was brought to you by Cision The following files are available for download:

Phase 3NDA

02 Apr 2024

·www.prnewswire.com

Mars Veterinary Health pilots industry-leading anaesthetic gas capture technology to reduce carbon emissions

World's leading provider of veterinary care will be first to introduce innovative in-clinic solution to support sustainability goals BIRMINGHAM, England, April 3, 2024 /PRNewswire/ -- Mars Veterinary Health, through its UK veterinary group Linnaeus and in partnership with Waltham Petcare Science Institute, today announced a first-of-its-kind partnership with SageTech Veterinary to pilot an innovative anaesthetic gas capture solution to help prevent harmful greenhouse gases from entering the atmosphere. During a typical anaesthetic procedure, less than five percent of the volatile anaesthetic agent delivered to a patient is absorbed and metabolised, leaving approximately 95 percent it to be exhaled. Continue Reading Mars Veterinary Health pilots industry-leading anaesthetic gas capture technology to reduce carbon emissions SageTech's trusted gas-capture technology—which is currently used in human healthcare—works by capturing the waste anaesthetic agent breathed out during an operation by safely adsorbing it into a specially developed reusable capture canister. These waste anaesthetic agents can then be extracted from the filter, avoiding current routes for disposal of volatile anaesthetic agents of incineration or release into the atmosphere. "As a leading provider of veterinary care, we have a responsibility to take climate action at scale and lead the way toward more sustainable practices," said Ellie West, RCVS and EBVS® European Specialist in Veterinary Anaesthesia and Analgesia, and Linnaeus Environmental Sustainability Lead. "Our innovative collaboration should help us take a significant step forward in our sustainability journey, aimed at contributing to a better future for the planet—and the people and pets who depend on it." A veterinary-industry first, Mars Veterinary Health's one-year pilot will start with 10 Linnaeus primary care and referral veterinary practices in the UK with the aim of reducing anaesthesia-related carbon emissions resulting from release or disposal of these agents and determining the efficiency of capture in its clinics, ultimately supporting its goal of reducing climate-change impacts. Mars Veterinary Health aims to use these learnings to explore the potential application of this technology across other parts of its business in the years to come. "At SageTech Veterinary, we are excited to share our developed technology and work alongside Mars Veterinary Health to significantly reduce the carbon footprint associated with the direct release of waste volatile anaesthetic agents to the environment," said Iain Menneer, CEO of SageTech Medical. "It has been wonderful to work with the Linnaeus and Waltham teams, and we are confident this pilot project will demonstrate to the veterinary profession how such collaborations can be a collective force for good." This industry-first pilot in sustainable veterinary care is consistent with Mars, Incorporated's Net Zero Roadmap, a detailed action plan for achieving net zero greenhouse gas emissions by 2050, as well as details on the company's progress and history of working on climate action. Details about Mars, Incorporated's wider sustainability—including climate—work can be found in its Sustainable in a Generation Scorecard. About Mars Veterinary Health Mars Veterinary Health is a global division of Mars Petcare dedicated to delivering high-quality pet healthcare to further its collective Purpose: A BETTER WORLD FOR PETS™. Mars Veterinary Health's 70,000 Associates across 3,000 global veterinary clinics put pets, people, and the planet first. The Mars Veterinary Health family includes Associates at AniCura, Banfield, BluePearl, Creature Comforts, Gentle Oak, Hillside, Linnaeus, Mount Pleasant, Tai Wai, VCA, VES, and VSH who demonstrate compassion and expertise while enabling 35 million pet visits each year. Learn more at marsveterinary.com. About Linnaeus Part of Mars Veterinary Health, Linnaeus is a highly respected community of more than 50 primary care and 17 referral veterinary practices based in the UK. Linnaeus employs over 6,000 pet-loving Associates with some of the country's finest vet and nursing teams who together are committed to excellence and delivering high-quality care to patients. Learn more at linnaeusgroup.co.uk. About Mars Science & Diagnostics Mars Science & Diagnostics is a division of Mars Petcare, a diverse business dedicated to one purpose: A BETTER WORLD FOR PETS™. Science & Diagnostics brings together the power of leading pet health science with expertise across diagnostics, data, and technology to improve outcomes in pet health. Antech, our global veterinary diagnostics business, spans in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software; reference laboratories; veterinary imaging and technology; education; and telemedicine with board-certified specialist support services. Our at-home diagnostics offering includes Wisdom Panel, the world's most accurate pet DNA test. For 60 years, our Waltham Petcare Science Institute has been advancing science to better understand pet health. About SageTech Veterinary The manufacture of virgin anaesthetic agents and their release as waste volatile gases is highly damaging to the environment and contributes significantly to the total carbon footprint of healthcare. SageTech Veterinary is part of SageTech Medical, a medical device and pharmaceutical company focused on the research, design, manufacture, and distribution of technologies for the capture and recycling of waste volatile anaesthetic agents in human and animal healthcare. Their unique circular economy solution safely captures volatile anaesthetic agents (sevoflurane, isoflurane, desflurane) through actively controlled adsorption onto a reusable capture canister. Learn more at sagetechveterinary.com. Photo - SOURCE Mars PetCare

100 Deals associated with Isoflurane

External Link

KEGG	Wiki	ATC	Drug Bank
D00545	Isoflurane	N01AB06	DB00753

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	US	Baxter Healthcare Corp.	18 Dec 1979

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SFN2024	Not Applicable	-	-	Isoflurane (Male rats)	nboixyxrzi(ctqnmkhsmo) = neznvdqbsq dtgqbczitl (dedwpayqml )	-	08 Oct 2024
				Isoflurane (Female rats)	nboixyxrzi(ctqnmkhsmo) = vwaoqrcdps dtgqbczitl (dedwpayqml )
SFN2023	Not Applicable	-	-	isoflurane (Adult male rats)	cfhonsvccf(exohwqypqe) = qrlmojoujd pdysgacgvo (rnihmcoanv ) View more	-	13 Nov 2023
				isoflurane (Old male rats)	cfhonsvccf(exohwqypqe) = nmeozgovsm pdysgacgvo (rnihmcoanv ) View more
APAO2023	Not Applicable	-	-	Isoflurane (ChAT-IRES-Cre mice)	brgqofnhgz(zxeakxclqi) = vhplptvjrd urnivooubc (ovnogrztdz )	-	23 Feb 2023
				Isoflurane (Wildtype C57Bl/6J mice)	brgqofnhgz(zxeakxclqi) = stiqkjnoze urnivooubc (ovnogrztdz )
NCT03882788 (NDO, CTgov)	Not Applicable	Heart Defects, Congenital \| Maternal anesthesia and analgesia affecting fetus or newborn \| Neurodevelopmental Disorders	153	Fentanyl (high dose) (Narcotic Based Anesthesia)	iwljscwcfx(wzmxaguscq) = fnqrzvemsl xwelnlitab (ttwpqlawzr, owtvvdpjpe - qgiiiyqcuk) View more	-	09 May 2022
				Fentanyl (low dose)+Isoflurane (Volatile Anesthesia)	iwljscwcfx(wzmxaguscq) = bvbkhyzqjk xwelnlitab (ttwpqlawzr, yxtsjahkzw - tfsnufxraw) View more
EUCTR2016-004551-67-SI (Pubmed \| Lancet Respir Med)	Phase 3	-	338	Isoflurane via the Sedaconda anaesthetic conserving device	ydynuhpwnb(dkrhvmnkuq) = five [3%] vs four [3%] zzpggpeuaq (yjzwsuzftl ) View more	Positive	26 Aug 2021
				Propofol
NCT05830864 (Pubmed \| Neurocrit Care)	Not Applicable	Status Epilepticus	45	Isoflurane	vnxhnxrofc(uebforfaxk) = bnvxljezdn jjfgbmeopl (qvetilwymq )	-	20 Jul 2021
ESC2020	Not Applicable	Shock, Cardiogenic	32	Isoflurane sedation	yhmzlnlkkx(brcsqoinik) = yrpimdprzk nsgphmtdag (vvgsksjtrs ) View more	-	28 Aug 2020
				Intravenous sedation	yhmzlnlkkx(brcsqoinik) = xxtgmjyafa nsgphmtdag (vvgsksjtrs ) View more
NCT02111447 (CTgov)	Phase 4	Emergence Delirium	6	Propofol (Sevoflurane, Propofol, Nasal Oxygen)	okkodkdcin(uyucvnqhzb) = hioqitbijf suxyolrwso (pqkqwdoxab, qkqrzhumpv - jmkiamcmxp) View more	-	23 Jul 2019
				Sevoflurane (Sevoflurane, Sevoflurane, LMA)	okkodkdcin(uyucvnqhzb) = qpywnvasdl suxyolrwso (pqkqwdoxab, eybhtpywqk - vwwtxnwrom) View more
NCT02925611 (CTgov)	Phase 4	Emergence Delirium	60	Isoflurane (Isoflurane)	dvcelwtyio(smibjjirrz) = midzotbqxc gairzdjkql (zttimrzwwe, zyvtzublwg - vsyjvnhljy) View more	-	19 Jun 2019
				DESFLURANE (Desflurane)	dvcelwtyio(smibjjirrz) = qtzxhuxrzh gairzdjkql (zttimrzwwe, lxgxhaeqln - ghsnglzixr) View more
NCT02726620 (CTgov)	Not Applicable	Hypotension	22,435	Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Usual Care Group)	sgdtzlbphu(nhcabwduld) = skndqlbzpq qvpyjhdbce (nxsernacrk, srerdwlmbx - dfbmoqzpmn) View more	-	16 May 2019
				Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Hypotension Decision Support)	sgdtzlbphu(nhcabwduld) = zuydrtastu qvpyjhdbce (nxsernacrk, cgotohgene - dqappegizs) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis